99 related articles for article (PubMed ID: 19342181)
1. Mechanism of anti-angiogenic activities of chitooligosaccharides may be through inhibiting heparanase activity.
Quan H; Zhu F; Han X; Xu Z; Zhao Y; Miao Z
Med Hypotheses; 2009 Aug; 73(2):205-6. PubMed ID: 19342181
[TBL] [Abstract][Full Text] [Related]
2. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.
Zhao H; Liu H; Chen Y; Xin X; Li J; Hou Y; Zhang Z; Zhang X; Xie C; Geng M; Ding J
Cancer Res; 2006 Sep; 66(17):8779-87. PubMed ID: 16951194
[TBL] [Abstract][Full Text] [Related]
3. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.
Parish CR; Freeman C; Brown KJ; Francis DJ; Cowden WB
Cancer Res; 1999 Jul; 59(14):3433-41. PubMed ID: 10416607
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88.
Fairweather JK; Hammond E; Johnstone KD; Ferro V
Bioorg Med Chem; 2008 Jan; 16(2):699-709. PubMed ID: 17967543
[TBL] [Abstract][Full Text] [Related]
5. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening.
Hammond E; Li CP; Ferro V
Anal Biochem; 2010 Jan; 396(1):112-6. PubMed ID: 19748475
[TBL] [Abstract][Full Text] [Related]
6. Heparanase coagulation and cancer progression.
Nadir Y; Brenner B
Best Pract Res Clin Haematol; 2009 Mar; 22(1):85-92. PubMed ID: 19285275
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Heparanase-Mediated Angiogenesis Using Microvascular Endothelial Cells: Identification of λ-Carrageenan Derivative as a Potent Anti Angiogenic Agent.
Poupard N; Badarou P; Fasani F; Groult H; Bridiau N; Sannier F; Bordenave-Juchereau S; Kieda C; Piot JM; Grillon C; Fruitier-Arnaudin I; Maugard T
Mar Drugs; 2017 May; 15(5):. PubMed ID: 28486399
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).
Karoli T; Liu L; Fairweather JK; Hammond E; Li CP; Cochran S; Bergefall K; Trybala E; Addison RS; Ferro V
J Med Chem; 2005 Dec; 48(26):8229-36. PubMed ID: 16366604
[TBL] [Abstract][Full Text] [Related]
9. Involvement of heparanase in tumor metastases: a new target in cancer therapy?
Boyd DD; Nakajima M
J Natl Cancer Inst; 2004 Aug; 96(16):1194-5. PubMed ID: 15316047
[No Abstract] [Full Text] [Related]
10. New oligosaccharides prepared by acid hydrolysis of the polysaccharides from Nerium indicum Mill and their anti-angiogenesis activities.
Hu K; Liu Q; Wang S; Ding K
Carbohydr Res; 2009 Jan; 344(2):198-203. PubMed ID: 19054503
[TBL] [Abstract][Full Text] [Related]
11. Heparanase, tissue factor, and cancer.
Nadir Y; Vlodavsky I; Brenner B
Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
[TBL] [Abstract][Full Text] [Related]
12. [Heparanase: target for cancer metastatic therapy].
Zhao HJ; Zhang XW; Ding J
Yao Xue Xue Bao; 2005 Oct; 40(10):871-5. PubMed ID: 16408800
[No Abstract] [Full Text] [Related]
13. 2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors.
Courtney SM; Hay PA; Buck RT; Colville CS; Porter DW; Scopes DI; Pollard FC; Page MJ; Bennett JM; Hircock ML; McKenzie EA; Stubberfield CR; Turner PR
Bioorg Med Chem Lett; 2004 Jun; 14(12):3269-73. PubMed ID: 15149688
[TBL] [Abstract][Full Text] [Related]
14. Involvement of disulfide bond formation in the activation of heparanase.
Simizu S; Suzuki T; Muroi M; Lai NS; Takagi S; Dohmae N; Osada H
Cancer Res; 2007 Aug; 67(16):7841-9. PubMed ID: 17699790
[TBL] [Abstract][Full Text] [Related]
15. Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase.
Dai X; Yan J; Fu X; Pan Q; Sun D; Xu Y; Wang J; Nie L; Tong L; Shen A; Zheng M; Huang M; Tan M; Liu H; Huang X; Ding J; Geng M
Clin Cancer Res; 2017 Oct; 23(20):6267-6278. PubMed ID: 28710312
[No Abstract] [Full Text] [Related]
16. Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.
Ricciuti B; Foglietta J; Chiari R; Sahebkar A; Banach M; Bianconi V; Pirro M
Med Oncol; 2017 Dec; 35(1):4. PubMed ID: 29209837
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.
Jia L; Ma S
Eur J Med Chem; 2016 Oct; 121():209-220. PubMed ID: 27240275
[TBL] [Abstract][Full Text] [Related]
18. Oligosaccharides from fucosylated glycosaminoglycan prevent breast cancer metastasis in mice by inhibiting heparanase activity and angiogenesis.
Zhou L; Yin R; Gao N; Sun H; Chen D; Cai Y; Ren L; Yang L; Zuo Z; Zhang H; Zhao J
Pharmacol Res; 2021 Apr; 166():105527. PubMed ID: 33667689
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of vitamin K3 on DNA polymerase and angiogenesis.
Matsubara K; Kayashima T; Mori M; Yoshida H; Mizushina Y
Int J Mol Med; 2008 Sep; 22(3):381-7. PubMed ID: 18698499
[TBL] [Abstract][Full Text] [Related]
20. Heparanase: one molecule with multiple functions in cancer progression.
Vlodavsky I; Elkin M; Abboud-Jarrous G; Levi-Adam F; Fuks L; Shafat I; Ilan N
Connect Tissue Res; 2008; 49(3):207-10. PubMed ID: 18661344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
